We at ResMed strive to provide a continuum of care. That’s why we support and actively engage in research initiatives relating to type 2 diabetes, as part of a clinical focus related to sleep-disordered breathing.
Discover our research initiatives relating to type 2 diabetes below.
GLYCOSA
ResMed is conducting a clinical trial to evaluate the impact of continuous positive airway pressure (CPAP) therapy on glycaemic control (control of glucose in the blood) in type 2 diabetic patients with Obstructive Sleep Apnoea (OSA). GLYCOSA is the largest study of its kind and the first multicentre, randomised study comparing CPAP therapy to standard medical care in the treatment of patients with type 2 diabetes and OSA. 416 patients have been enrolled in this study across multiple sites in the US and Australia with results expected in the second part of 2014.
ROSA
ResMed is sponsoring the ROSA clinical trial, a multicentre, randomised controlled trial in the UK that enrols patients with type 2 diabetes, diabetic retinopathy and OSA. Patients are then treated with CPAP to determine whether 12 months of treatment improves their vision.
The ROSA study aims to enrol 150 patients.
For more information contact:
Trial Co-ordinator
Dr Ben Prudon:
07528 068251
ben.prudon@nuth.nhs.uk
Trial Manager
Emma Hedley:
01865 225550
emma.hedley@ouh.nhs.uk
ROSA Research Nurse
Joan Hughes:
0191 2231148
joan.hughes5@nuth.nhs.uk
For clinical literature on sleep apnoea and type 2 diabetes, consult our dedicated ResMed page